	Genetic Carrier	
A Sonic Healthcare Anatomic Pathology Practice	and Prenatal Screening Requisition	ACCESSION LABEL
PATIENT INFORMATION		
	Biological Sex	
Last Name M	I. L L Female Male	
First Name		
Street Address	Apt #	
City St	ate Zip Code	LE COLLECTION — (Complete A, B, and C)
Date of Birth Medical Record # F		ection Date (MM/DD/YYYY):
B		ection Time:epatient's full name and date of birth on all tubes
Insurance Name	collection of the ge and I will consent fr diagnosis	pply information to the patient regarding genetic testing, including: the manner of n, use, retention, maintenance, and disclosure of the patient's sample and the results enetic testing; and the benefits, risks, and limitations of the laboratory test requested; answer any of the patient's questions. I understand that the patient must give voluntary for genetic testing to be performed. Any testing ordered is medically necessary for the s or detection of disease, illness, impairment, symptom, syndrome, or disorder, and ts will be used in the medical management and treatment decisions for the patient are medically necessary for the diagnosis or treatment of the patient.
Subscriber Name ID #	Physicial Physicial tests that	as which be deed in the inductant management and treatment decisions for the patient, ans (or other individuals authorized by law to order tests) should only order at are medically necessary for the diagnosis or treatment of the patient.
Group # Preau	uthorization # Clinici	vian Signature Date
PATIENT SIGNATURE FC	OR INFORMED CONSENT AND	D FINANCIAL RESPONSIBILITY
collect, obtain, use, maintain, and retain a sample and the results of the testing for that purpose. I authorize the laboratory to disclose my medical information, including the results of my genetic testing, to the ordering clinician or healthcare provider for treatment purposes; Metis Genetics, LLC for purposes of genetic counseling when appropriate; and my health plan/ insurance carrier and its authorized representatives as necessary for reimbursement unless otherwise indicated. I have had the opportunity to ask questions and discuss the capabilities, limitations, and possible risks of the test(s) with my healthcare provider and have been made aware of the valiability of genetic counseling.		
I accept full financial responsibility for any payment obligation associated with my test(s).		gnature Date
raon invasive i renatat sereening (ian s)	Collect ONE Streck tube Genetic C	Carrier Screening (CS) Collect TWO EDTA purple-top tubes/test
<sup>1</sup> Singletons Only <sup>2</sup> Fetal Sex Not Reported Please select ONLY ONE of the below test options If twins, only test code W907 or W906 is appropriate. With Fetal Sex Without Fetal S	Ow139 CF 13 Ow199 Fragil	le X Screen eflex Methylation <sup>++</sup> O W559 Classic Panel, Female (24 genes) <sup>++</sup>
O W905 NIPS W/ SCA <sup>1+</sup> (Trisomies 21, 18, 13, W/ Sex Chromosome Aneuploidies)         O W906 NIPS <sup>2+</sup> (Trisomies 21, 18, 13, 13)           O W907 NIPS, Twin <sup>+</sup> (Trisomies 21, 18, 13)         O W910 NIPS W/ SC (W910 NIPS W/ SC (Trisomies 21, 18, 13, W)           O W913 NIPS+ w/ Microdeletions <sup>1+&gt;</sup> (Trisomies 21, 18, 13, W/ Sex Chromosome Aneuploidies and Microdeletions)         O W915 NIPS+ W/ I (Trisomies 21, 18, 13, W)	CA <sup>1,2+</sup> Sex Chromosome AneuploIdies) Vicrodeletions <sup>1,2+&gt;</sup>	c Trio, Female <sup>+&gt;*</sup> O W555 Complete Panel, Female (157 genes) <sup>+&gt;</sup> O W556 Complete Panel, Male (147 genes) <sup>+</sup>
O Other Code:		al Information (Required)
NIPS Clinical Information (Required)         Number of Fetuses:       (S)ingleton         (T)wins Maternal Weight (lbs):         Estimated Date of Delivery (EDD):       /         //       Maternal Height (in):         IVF Pregnancy:       Y         N       N Patient/donor egg retrieval age:		sity:       African American (AA)       Caucasian (W)       Hispanic (H)         Jewish (Ashkenazi) (J)       Other (O):       Not Specified (NS)         JS (US)       Egg/Sperm Donor (DO)       Consanguinity (CO)         Dataset (awur (arrist (O))       Detiant (awur (arrist (O))
NIPS Commonly Utilized ICD Codes (Required)		Partner Known Carrier (PC) Patient Known Carrier (PT) (HX)
O 009.291 Other poor reproductive or obstetric history, 1st tri       O 213.79 Other genetic screening         O 009.511 Elderly primigravida, 1st tri       O 33.1 Pregnant state, incidental         O 009.519 Elderly primigravida, 1st tri       Z34.01 Normal first pregnancy, 1st tri         O 009.521 Elderly multigravida, 1st tri       Z34.90 Other normal pregnancy, 1st tri		y Present:       Y       N       If Yes, Indicate Relative:         Parent       Grandparent       Aunt/Uncle       Niece/Nephew       Cousin         Affected by       Or       Carrier of
O 009.529 Elderly multigravida, unsp tri unsp tri		
÷		er primary ovarian failure
genetic finding O 35.1XX0 (Suspected) chromosomal abnormality in fetus For test and panel details, please visit www.SonicReprodu	of congenital anomalies code): C31.430 Enc O Z31.440 Enc O Z81.0 Family O Z82.69 Family	counter of female for testing for genetic disease carrier status for procreative mgmt counter of male for testing for genetic disease carrier status for procreative mgmt ly history of intellectual disabilities nily history of other diseases of the musculoskeletal system and connective tissue nily history of carrier of genetic disease

Rep
Prenatal

[38773]





### Non-Invasive Prenatal Screening \_\_\_\_

### What is NIPS?

NIPS is a non-invasive blood test that screens for chromosome conditions in the pregnancy. These conditions are uncommon, do not usually run in the family, and can happen in any pregnancy. NIPS can be performed based on a single blood draw beginning at 10 weeks gestation. Collecting your blood sample for NIPS poses no threat to your baby.

### What does NIPS test for?

**Chromosome Conditions** 

- Trisomy 21 (Down syndrome)
- Trisomy 18 (Edwards syndrome)
- Trisomy 13 (Patau syndrome)

Additional testing options are available, including fetal sex. Limitations and indications for screening for additional conditions should be discussed with your provider.

### How accurate is NIPS?

NIPS is a screening test. While uncommon, some people may receive a positive result when the pregnancy is unaffected or a negative result when the pregnancy is affected. Testing for rarer conditions may negatively impact accuracy and increase the probability of a positive result being a false positive.<sup>1</sup> Any high-risk results should be confirmed with diagnostic laboratory testing.

### Carrier Screening

### What is a carrier?

A carrier is a person who has a genetic change, or mutation in their DNA, but, in most cases, does not have any associated health problems.

# What does reproductive carrier screening test for?

Our test will help identify carriers for the main genetic disorders:

- Cystic Fibrosis (CF)
- Spinal Muscular Atrophy (SMA)
- Fragile X Syndrome (FX)\*
- Hemoglobinopathy Screening (such as sickle cell anemia)
- Ashkenazi Jewish Panel
- Expanded Carrier Panel Options

### **Results**

Your results will be delivered to your provider, and he or she will discuss them with you. They will also be available to you in your SonicMyAccess™ patient portal.

Finding out about a genetic condition can raise important concerns around pregnancy planning and care. If it is determined you have a high-risk pregnancy, a licensed genetic counselor will reach out to you to provide education about what your results mean.\*

\*Patients must be enrolled with SonicMyAccess<sup>™</sup> and confirm their enrollment with our genetic counseling service to have the benefit of this offering.

### Why test for these conditions?

CF, SMA, and FX are three of the most commonly inherited conditions. People are usually unaware that they are carriers and often do not have a history of these conditions in their family.

- CF is one of the most common life-limiting genetic conditions.
- SMA is the most common genetic cause of death in children under the age of two.
- FX is the most common form of inherited intellectual disability.



## For patient resources and consent forms, please visit www.SonicReproductiveHealth.com

Important Test Information NIPS is a screening test, therefore false-negative or false-positive results can occur. Carrier conditions including but not limited to blood transfusion, organ transplantation, bone marrow transplant, certain surgical procedures, stem cell therapy, malignancy, or genetic mosaicsm can affect test accuracy. Hegnancy-related conditions such as fetal or placental genetic mesaicsm, nonviable twin, or fetal demise can decrease test accuracy. There are exceptional and uncommon situations, which is why INPS should be regarded as a screening test. There is a small, well-defined possibility that NIPS will not reflect the actual chromosome status of the fetus. A "high-probability" result may still warrant invasive genetic testing if there are other indicators of a fetal chromosome disorder. NIPS does not detect all genetic defects or non-genetic or structural birth defects. Conclusions about the fetal condition and pregnancy management decisions should not be solely based on the results of this screening test alone.

It is important to note that no pre-conception **carrier screen** is able to detect every mutation that might cause a genetic condition. The test does not detect every mutation that can cause cystic fibrosis, spinal muscular atrophy, and fragile X syndrome, or mutations in other genes responsible for other disorders. If no mutation is found, the risk of the patient being a carrier for these conditions is greatly reduced; however, the possibility cannot be eliminated. The patient's ethnicity may also affect carrier risk.

NIPS was developed and its performance characteristics determined by Sonic Reference Laboratory (SRL). It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes and should not be regarded as investigational or for research. SRL is qualified to perform high-complexity testing under the Clinical Laboratory improvement Amendments (CLIA).

Copyright @ 2024 Sonic Healthcare USA Inc. All rights reserved. All of the information in this document is the property of Sonic Healthcare USA. It may not be distributed, transmitted, reproduced, copied or displayed without the written permission of Sonic Healthcare USA. Sonic Healthcare USA, including its affiliates, does not dispense medical advice. The content in this marketing collateral is intended for informational purposes only and does not constitute legal, medical or any professional advice. Please consult your physician or a healthcare provider for additional information.

\*Routine reproductive carrier screening for FX in male patients is not recommended.

#### References

1. https://www.ajog.org/article/S0002-9378(17)31187-0/pdf

### Advancing **Personalized Reproductive Care** With an Inclusive and Empowered Approach